Ferrer and Verge Genomics have entered into a collaboration to jointly advance the experimental treatment for ALS, designated as VRG50635, into clinical trials.

Phagocytosis is an essential immune response where phagocytes consume foreign particles, dead cells, and pathogens like bacteria and viruses.

Astria Therapeutics Reveals Encouraging Early Findings in ALPHA-STAR Phase 1b/2 Study for HAE with STAR-0215.

Carbamazepine, a minuscule molecule drug, exerts its therapeutic effect through the blocking of sodium channels in the human body.

Ultomiris receives US green light to treat adult patients with spectrum disorder related to neuromyelitis optica (NMOSD).

This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.

Nitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024.

Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).

Chugai Pharmaceutical revealed Phase III LUMINESCE trial results for their drug Enspryng (satralizumab).